Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
Todayโs edition tracks a simple pattern: Washington is still deciding how fast to squeeze intoxicating hemp, California keeps losing ground when tax policy whipsaws, and New York just put an insider in charge to rebuild trust through execution. We close the week with labor pressure and capital discipline as the quiet forces separating durable operators from the rest.
You will see us again Sunday morning, and The Hybrid drops a new episode Monday.
๐งพ Federal Hemp Clock
๐ California Revenue Pressure
๐๏ธ New York Leadership Reset
The time to repair the roof is when the sun is shining.
What Will Your Retirement Look Like?
Planning for retirement raises many questions. Have you considered how much it will cost, and how youโll generate the income youโll need to pay for it? For many, these questions can feel overwhelming, but answering them is a crucial step forward for a comfortable future.
Start by understanding your goals, estimating your expenses and identifying potential income streams. The Definitive Guide to Retirement Income can help you navigate these essential questions. If you have $1,000,000 or more saved for retirement, download your free guide today to learn how to build a clear and effective retirement income plan. Discover ways to align your portfolio with your long-term goals, so you can reach the future you deserve.

Fast-moving headlines, flagged for what matters.
A House farm bill fight is forming around whether to pause looming federal hemp changes that would squeeze intoxicating hemp products later this year. Supporters pitch transition time for farmers, manufacturers, and regulators who built businesses inside a murky federal lane. Opponents argue a delay extends the period where high potency products sit in broad retail with youth access and enforcement confusion riding shotgun. Kentucky politics are driving some of the pressure, including outreach aimed at Sen. Mitch McConnell. Congress now has to pick a posture: force a fast reset with predictable disruption, or keep outsourcing the mess to states and local enforcement. (The Fence Post)
๐งโโ๏ธ Indiana Moves To Turn Hemp Into A Policing Question
Indiana Attorney General Todd Rokita is urging House members to adopt the Senate version of SB 250 and align state law with what he describes as the new federal hemp definition taking effect in late 2026. He is selling it as public safety cleanup, with intoxicating products framed as a loophole market hiding in plain sight. The politics are clean because โmatch federal lawโ gives lawmakers a simple script and gives enforcement a clearer lane. The policy risk is blunt drafting, because a broad hammer can hit disciplined, age-gated low-dose beverages and lawful CBD supply chains if definitions are sloppy. The real fight lands on line drawing: what Indiana bans, what it regulates, and who gets authority to enforce it. (WBIW)
California licensed retailers reported about $3.9 billion in cannabis sales in 2025, down from $4.2 billion in 2024, extending a multi-year slide. A temporary excise tax hike from 15% to 19% took effect July 1st and was repealed October 1st, adding friction during peak competition with cheaper unregulated options. Fourth-quarter sales still fell year over year after the rollback, which points to deeper trust and channel issues beyond a single tax quarter. Unit volume barely moved and prices only dipped modestly, so the problem reads like where people buy, not whether they buy. Sacramentoโs credibility takes the hit when tax mechanics feel unstable, because instability sends shoppers to the one market that never changes its rules. (MJBizDaily)
Governor Kathy Hochul appointed John Kagia as Acting Executive Director of the New York Office of Cannabis Management. An internal pick signals stability, and New York needs administrative tempo more than a new public face. Kagia inherits a trust deficit across licensees, legislators, litigants, local governments, and staff who have lived through churn. Acting status keeps Senate confirmation in play, which becomes an early test of whether Albany wants competence with runway or another round of politics. This is a capable appointment if he is given tools and space, because rebuilding confidence in New York will come from repeatable execution, not grand announcements. (Office of Governor Kathy Hochul)
Cannabis companies keep flirting with share repurchases while capital stays expensive and unpredictable. Green Thumb and Cronos can justify buybacks from positions of balance sheet strength, and that distinction matters. The risk appears when repurchases become messaging instead of strategy, especially for companies facing heavy tax drag, debt service, or working capital strain. Investors applaud confidence until a downturn forces a raise, then they punish the teams that burned liquidity to manufacture one good quarter of optics. Boards that treat cash as runway will outlast boards that treat cash as applause. (New Cannabis Ventures)
Teamsters Local 429 says workers at Cresco Labsโ Sunnyside dispensary in Wyomissing, Pennsylvania are on strike over wages and hours after bargaining failed to land a contract the union views as fair. The union is trying to set an industry baseline, because cannabis retail is aging into normal labor expectations. For Cresco, the exposure goes beyond one store because disruption travels fast in a regulated business that runs on staffing stability and customer experience. A prolonged strike also becomes a governance problem, since investors tolerate external volatility and lose patience with avoidable operational self-harm. The operational fix is simple to say and hard to do: settle quickly, keep standards sustainable, and stop letting labor become the story. (PR Newswire)
Vermont State Police arrested a Barre-area cultivator on allegations he grew and sold cannabis outside the regulated system. Diversion lands harder than routine noncompliance because it challenges the stateโs core promise that licensed supply is tracked, tested, and accountable. Vermontโs Cannabis Control Board now has to move fast enough to protect legitimacy without turning one case into a stain on every compliant operator. Public confidence erodes when traceability gets pierced, and lawmakers start asking whether oversight is performative. Market fairness erodes too, because untracked product undercuts the businesses paying for compliance. (WCAX)
U.S. and Canadian operators are moving into Europe early, betting medical frameworks will widen into durable scaled channels. The posture shift matters because the talk is turning to GMP, distribution mechanics, and reimbursement instead of legalization slogans. France is a key watch if reimbursement rates take shape while THC limits stay tight and smokable flower remains off the table, which will influence whether patients and legacy consumers migrate into the legal lane. For U.S. operators boxed in by a fragmented domestic map, Europe offers fewer jurisdictions and clearer national gates, and it rewards process discipline. The risk is timing and product fit, because infrastructure can get built faster than demand if rules land too restrictive. (MJBizDaily)
Reporting from The Safety Magazine highlights injured workers increasingly turning to medical cannabis when conventional pain treatments fail or create side effects they cannot tolerate. The shift lands inside workersโ compensation systems that were built around pharmaceuticals and procedure codes, not plant-based alternatives. Insurers are watching cost exposure and impairment risk, pharmacy benefit managers are watching formulary disruption, and employers are watching workplace safety standards. Lower treatment costs do not disappear; they get absorbed somewhere in the system, which makes reimbursement policy a live financial question, not a philosophical one. States that clarify medical oversight, impairment standards, and payment rules early will shape whether cannabis becomes a managed cost tool or an unmanaged gray expense. (The Safety Magazine)
Alberta will eliminate the 2% early payment fee producers paid when they opted for faster payment from Alberta Gaming, Liquor and Cannabis. The fee attached to getting paid in 15 days instead of 60, turning liquidity into a toll. Dropping it is a small administrative move with real balance sheet impact for producers still managing fragile cash cycles. Expect more producers to choose faster payment now that it no longer comes with a haircut, which can stabilize supply commitments and reduce financing pressure. Governments earn credibility when they stop nickel-and-diming the supply base, especially before the next round of policy changes. (StratCann)
A service is rolling out cannabis kiosks in Arizona independent living communities, pitching convenience and education for older adults. The operational upside is reduced friction for residents who already use cannabis and want predictable access without a retail trip. The regulatory risk sits in role clarity, because on-site โeducationโ can drift into unlicensed sales activity if controls, scripts, and supervision are sloppy. If this scales, regulators will face pressure to draw a bright line between permitted education and regulated retail conduct inside these facilities. The larger signal is cultural and administrative: cannabis is entering institutional spaces that still run on medication-level expectations of seriousness and compliance. (Marijuana Moment)
Become An AI Expert In Just 5 Minutes
If youโre a decision maker at your company, you need to be on the bleeding edge of, well, everything. But before you go signing up for seminars, conferences, lunch โn learns, and all that jazz, just know thereโs a far better (and simpler) way: Subscribing to The Deep View.
This daily newsletter condenses everything you need to know about the latest and greatest AI developments into a 5-minute read. Squeeze it into your morning coffee break and before you know it, youโll be an expert too.
Subscribe right here. Itโs totally free, wildly informative, and trusted by 600,000+ readers at Google, Meta, Microsoft, and beyond.
๐ Morningstar read Green Thumbโs quarter as legalization tailwinds that still cannot outrun price compression, even for a top-tier operator. The point is capital discipline, because when pricing keeps sliding, balance sheet choices decide who earns staying power. (Morningstar)
๐งฌ CBG and CBG-A are drawing renewed attention as non-intoxicating cannabinoids with early signals in stress, inflammation, and cardiovascular pathways. I have been increasingly fascinated by CBGโs potential, particularly as research starts to move beyond novelty and into mechanism. The policy test will be marketing discipline, because as interest grows, regulators and credible brands will need to keep claims tethered to evidence. (Cannabis Health News)
๐ WebMD walked through the growing gap between consumer experience and clinical research on cannabis and sleep, especially around sleep apnea and long-term sleep quality. Many patients report falling asleep faster, while controlled studies show mixed results on REM disruption, breathing irregularities, and sustained sleep architecture. The policy implication is straightforward: as cannabis moves deeper into wellness positioning, regulators and brands will face sharper scrutiny on sleep-related claims that outpace the evidence base. (WebMD)
๐๏ธ NORMLโs Paul Armentano argues the New York Times is blaming legalization for outcomes driven by tax load, retail friction, and a market design that keeps handing volume to unregulated sellers. He also separates state-regulated cannabis from gas-station intoxicating hemp, which matters because muddled categories produce muddled enforcement. (LA Progressive)
โ๏ธ A Milwaukee County judge criticized persistent marijuana odor in the courthouse as a decorum and professionalism problem. Legalization normalizes use, and institutions like courts still run on expectations of sobriety, so this friction will keep surfacing until norms and enforcement catch up. (FOX6 Milwaukee)
๐ง Missouri lawmakers advanced a psychedelics package that builds research and access pathways around psilocybin and ibogaine. Missouri is laying process rails now, which positions the state to move quickly if FDA approvals arrive and other states are still debating structure. (Marijuana Moment)






